Navigation Links
Hospira Reports Fourth-Quarter and Full-Year 2007 Results
Date:2/28/2008

-- Provides Sales and Earnings Projections for 2008 --

LAKE FOREST, Ill., Feb. 28 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the fourth quarter and full year ended Dec. 31, 2007.

Fourth Quarter:

-- Net sales increased 33.9 percent to $946.1 million in the fourth

quarter of 2007, compared to $706.5 million in the fourth quarter last

year. Net sales excluding Mayne Pharma sales grew 8.4 percent.

-- Adjusted* fourth-quarter 2007 diluted earnings per share were $0.63

versus $0.43 in 2006. GAAP fourth-quarter 2007 diluted earnings per

share were $0.47 versus $0.30 for the same period last year.

Full Year:

-- Net sales increased 27.8 percent to $3.44 billion versus $2.69 billion

in 2006. Net sales excluding Mayne Pharma sales grew 4.1 percent.

-- Adjusted* full-year 2007 diluted earnings per share were $2.19 versus

$1.94 last year. GAAP full-year 2007 diluted earnings per share were

$0.85 versus $1.48 in 2006.

"In 2007, Hospira delivered another strong year of revenue and profit growth, and we are energized as we begin 2008," said Christopher B. Begley, chairman and chief executive officer. "We are advancing our global performance and long-term goals with an increased focus on innovating our products and business to meet healthcare needs worldwide."

Significant Events in 2007

-- Completed the Mayne Pharma acquisition and made significant progress

integrating the two organizations. Hospira attained its acquisition-

related operational and financial milestones, including red
'/>"/>

SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. Hospira Launches Generic Irinotecan Injection
2. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
3. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
4. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
5. Hospira Reports Third-Quarter 2007 Results
6. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
7. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
8. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
9. Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter
10. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
11. J.D. Power and Associates Reports: Riverview Medical Center Recognized for Providing an Emergency Department Experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- The older ... the late 1990s is more effective than the current ... Teenagers who received four shots with the older vaccine ... years old were significantly less likely to become infected ... compared to children who received all of their immunizations ...
(Date:5/20/2013)... ARBOR, Mich. As high schoolers prepare for final ... "study drug" -- a prescription stimulant or amphetamine -- ... of Michigan poll shows only one in 100 parents ... has used a study drug., Study drugs refer to ... deficit hyperactivity disorder (ADHD); commonly prescribed medicines in this ...
(Date:5/20/2013)... May 20, 2013 Medicare Part D ... satisfied, citing lower costs, convenient access to pharmacies and ... Research Associates released today by the Pharmaceutical Care Management ... (9.5 million) are currently enrolled in plans with preferred ... and overall value of plans with preferred pharmacy networks,” ...
(Date:5/20/2013)... It’s May which means it’s Bike Month! If you ... those dusty bikes and helmets. , Windsong Production's and BLARE ... the office with Windsong Productions challenging BLARE ... miles for the 4th Annual Million Mile Challenge. They may ... *insert battle prep montage* , This is all part of ...
(Date:5/20/2013)... 20, 2013 6Webs.com is the leading ... reviews . 6Webs.com recently completed their assessments of the ... are completed annually and the top home security system ... their monitoring technology, equipment and warranties to mention a ... the 6Webs.com team completed the home security reviews, numerous ...
Breaking Medicine News(10 mins):Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2
... oral drug bosentan (Tracleer) has led to significant improvements ... PAH) // . ,PAH is usually linked with ... cause the overproduction of endothelin, which increases the chance ... obstruction leads to PAH, a condition that in most ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... to latest research patients who were treated for depression ... vitamin B12 in their blood.// An increasing amount of ... and depression, but the specifics have not been understood. ... of vitamin B12 and the treatment of depression. ...
... researchers find people who get only four hours a night have ... to weight gain. ,An investigation was conducted among 12 ... the study started, after they had slept about four hours a ... hours a night for two nights. Levels of leptin, which sends ...
... the market are losing their effectiveness, since most of ... that the ocean is a new place to look ... microorganisms fill every milliliter of seawater. Each one could ... deadliest diseases. Many marine organisms are already in development ...
... a month’s time from now five-year-old Hussain Abbas and Mohamed ... as normal children.// Part of a contingent of 20 Iraqi ... complicated cardiac problems by the Much Acclaimed heart surgeon Dr ... assessment this evening by a paediatric cardiac physician and are ...
Cached Medicine News:
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/19/2013)... ORLANDO, Fla. , May 19, 2013 /PRNewswire/ ... power and low temperature radiofrequency (RF) energy is ... and eliminates or reduces the need for medication ... long-term assessment presented today at the Digestive Disease ... Orlando, Florida . ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
... Inc., a market leader in PyroCarbon orthopedic implants, announces ... than 40,000 PyroCarbon extremity joint replacements worldwide. ... of Ascension Orthopedics, pioneered efforts using PyroCarbon in the ... His collaborative efforts with the Mayo Clinic lead to ...
... Reportlinker.com announces that a new market research report ... Probiotics and Prebiotics in Clinical Nutrition ... Overall sales of clinical nutrition products are ... EU as well as rising incidence of illnesses and ...
Cached Medicine Technology:Ascension Orthopedics Reaches Milestone With Distribution of 40,000 PyroCarbon Implants 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 3Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 4
...
Malis Curette, bayonet, titanium handle, stainless steel shaft, working distance 102 mm, length 203 mm....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm....
Medicine Products: